Development and validation of novel sepsis subphenotypes using trajectories of vital signs.

"Declarations Conflicts of interestSVB is supported by the ATS-GSK Research Grant in COVID-19 and by NIH/NIGMS K23GM144867. MMC is supported by NIGMS (R01GM123193), Department of Defense (W81XWH-21-1-0009), NIA (R21 AG068720), and NIAAA (R01 DA051464-01). MMC has a patent pending (ARCD. P0535US.P2) for risk stratification algorithms for hospitalized patients and has received research support from EarlySense (Tel Aviv, Israel). CMC is supported by funding from the National Institutes of Health (GM072808, GM104323, AA027396). ETQ was supported by NHLBI T32HL087738. CR was supported by NCATS UL1TR002378. Conflicts of interest SVB is supported by the ATS-GSK Research Grant in COVID-19 and by NIH/NIGMS K23GM144867. MMC is supported by NIGMS (R01GM123193), Department of Defense (W81XWH-21-1-0009), NIA (R21 AG068720), and NIAAA (R01 DA051464-01). MMC has a patent pending (ARCD. P0535US.P2) for risk stratification algorithms for hospitalized patients and has received research support from EarlySense (Tel Aviv, Israel). CMC is supported by funding from the National Institutes of Health (GM072808, GM104323, AA027396). ETQ was supported by NHLBI T32HL087738. CR was supported by NCATS UL1TR002378."

"Declarations: Conflicts of interestSVB is supported by the ATS-GSK Research Grant in COVID-19 and by NIH/NIGMS K23GM144867. MMC is supported by NIGMS (R01GM123193), Department of Defense (W81XWH-21-1-0009), NIA (R21 AG068720), and NIAAA (R01 DA051464-01). MMC has a patent pending (ARCD. P0535US.P2) for risk stratification algorithms for hospitalized patients and has received research support from EarlySense (Tel Aviv, Israel). CMC is supported by funding from the National Institutes of Health (GM072808, GM104323, AA027396). ETQ was supported by NHLBI T32HL087738. CR was supported by NCATS UL1TR002378. Conflicts of interest: SVB is supported by the ATS-GSK Research Grant in COVID-19 and by NIH/NIGMS K23GM144867. MMC is supported by NIGMS (R01GM123193), Department of Defense (W81XWH-21-1-0009), NIA (R21 AG068720), and NIAAA (R01 DA051464-01). MMC has a patent pending (ARCD. P0535US.P2) for risk stratification algorithms for hospitalized patients and has received research support from EarlySense (Tel Aviv, Israel). CMC is supported by funding from the National Institutes of Health (GM072808, GM104323, AA027396). ETQ was supported by NHLBI T32HL087738. CR was supported by NCATS UL1TR002378."